Amicus Therapeutics (FOLD) Sets New 52-Week Low at $9.84

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $9.84 and last traded at $10.14, with a volume of 1042971 shares. The stock had previously closed at $10.29.

Several research firms have recently issued reports on FOLD. ValuEngine upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 10th. BidaskClub lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 28th. Chardan Capital lowered shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $18.00 to $15.00 in a report on Friday, August 17th. Finally, Cowen restated a “buy” rating and issued a $31.00 target price on shares of Amicus Therapeutics in a report on Friday, October 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.50.

The firm has a market capitalization of $1.89 billion, a PE ratio of -3.56 and a beta of 1.48. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.03 and a current ratio of 9.12.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.04). The firm had revenue of $20.60 million during the quarter, compared to the consensus estimate of $23.56 million. Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. Amicus Therapeutics’s revenue was up 89.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.41) EPS. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post -1.2 earnings per share for the current year.

In related news, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $12.23, for a total transaction of $122,300.00. Following the completion of the sale, the chief financial officer now owns 127,622 shares in the company, valued at approximately $1,560,817.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were bought at an average price of $12.53 per share, with a total value of $626,500.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 620,000 shares of company stock valued at $7,505,000 in the last quarter. 2.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in FOLD. Principal Financial Group Inc. lifted its holdings in Amicus Therapeutics by 7.2% during the 1st quarter. Principal Financial Group Inc. now owns 134,648 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 9,027 shares in the last quarter. Xact Kapitalforvaltning AB raised its holdings in shares of Amicus Therapeutics by 14.0% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 29,241 shares of the biopharmaceutical company’s stock valued at $457,000 after purchasing an additional 3,600 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $318,000. Amalgamated Bank raised its holdings in shares of Amicus Therapeutics by 16.1% in the 2nd quarter. Amalgamated Bank now owns 28,896 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 4,011 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Amicus Therapeutics by 1.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 776,230 shares of the biopharmaceutical company’s stock valued at $12,125,000 after purchasing an additional 10,809 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics (FOLD) Sets New 52-Week Low at $9.84” was originally reported by WKRB News and is owned by of WKRB News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/23/amicus-therapeutics-fold-sets-new-52-week-low-at-9-84.html.

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Article: Stop Order

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply